Angelucci Brings Global Experience in Validation, cGMP to Leadership Role in Regulatory Affairs Division
CINCINNATI, April 12, 2005 -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced the appointment of Louis A. Angelucci III as Vice President, Validation, for its AAC Consulting Group, Inc., subsidiary based in Rockville, Md. Angelucci will oversee the day-to-day operations of the validation unit and maintain the quality and consistency of its service to clients.
Angelucci most recently served as Senior Director of Validation and Compliance in the life sciences division of global engineering and construction firm Technip. His prior experience includes serving as Vice President of Validation Operations for a major pharmaceutical firm, and responsibility for the global validation activities for two international companies.
"Lou brings more than 20 years experience in all aspects of cGMP, validation and validation project management to Kendle," says Edward A. Steele, Vice President of U.S. Regulatory Consulting and Submissions. "He also has experience working on commissioning, validation and cGMP issues with clients around the globe, and is familiar with U.S. and European regulations."
Angelucci earned Master of Science degrees in Engineering Management from Drexel University in 1990, and in Biomedical Engineering from the University of Pennsylvania in 1980. He earned a Bachelor of Science in biology from Ursinus College in 1977.
Angelucci is a member of the International Society of Professional Engineers (IPSE) and the board of directors of the Institute of Validation Technology (IVT). He serves as adjunct professor at both Temple University and the Stevens Institute of Technology. He also is a member of the industry advisory board for the Stevens Institute.
About Kendle
Kendle International Inc. (Nasdaq: KNDL) is among the world's leading global clinical research organizations. We deliver innovative and robust clinical development solutions--from first-in-human studies through market launch and surveillance--to help the world's biopharmaceutical companies maximize product life cycles and grow market share. With the expertise of our more than 1,700 associates worldwide, Kendle has conducted clinical trials or provided regulatory, pharmacovigilance and validation services in 70 countries. Investor kits are available upon request from Kendle, 1200 Carew Tower, 441 Vine Street,Cincinnati, OH 45202, or from the company's Web site at www.kendle.com.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.